Avenue Therapeutics Stock Today
| ATXI Stock | USD 1.90 0.07 3.83% |
Performance0 of 100
| Odds Of DistressOver 84
|
Avenue Therapeutics is trading at 1.90 as of the 10th of December 2024. This is a 3.83 percent increase since the beginning of the trading day. The stock's open price was 1.83. Avenue Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 10th of November 2024 and ending today, the 10th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 27th of June 2017 | Category Healthcare | Classification Health Care |
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acuteintensive care hospital setting. The company was incorporated in 2015 and is based in New York, New York. Avenue Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 1.91 M outstanding shares of which 44.05 K shares are presently shorted by private and institutional investors with about 0.73 trading days to cover. More on Avenue Therapeutics
Moving together with Avenue Stock
| 0.72 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.69 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Avenue Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Avenue Stock Highlights
| Executive President | Srinivas Subramanian | |||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsAvenue Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Avenue Therapeutics' financial leverage. It provides some insight into what part of Avenue Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Avenue Therapeutics (ATXI) is traded on NASDAQ Exchange in USA. It is located in 1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154 and employs 3 people. Avenue Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.5 M. Avenue Therapeutics conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 1.91 M outstanding shares of which 44.05 K shares are presently shorted by private and institutional investors with about 0.73 trading days to cover.
Avenue Therapeutics currently holds about 890 K in cash with (9.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6.
Check Avenue Therapeutics Probability Of Bankruptcy
Ownership AllocationAvenue Therapeutics shows 9.85 percent of its outstanding shares held by insiders and 10.33 percent owned by other corporate entities.
Check Avenue Ownership Details
Avenue Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Armistice Capital, Llc | 2024-09-30 | 115 K | |
| Sabby Management Llc | 2024-06-30 | 37.4 K | |
| Moss Adams Wealth Advisors Llc | 2024-09-30 | 11 K | |
| Ubs Group Ag | 2024-09-30 | 6.1 K | |
| Tower Research Capital Llc | 2024-09-30 | 1.7 K | |
| Wells Fargo & Co | 2024-09-30 | 561 | |
| Bank Of America Corp | 2024-09-30 | 10.0 | |
| Royal Bank Of Canada | 2024-06-30 | 8.0 | |
| Emfo, Llc | 2024-06-30 | 8.0 | |
| Jpmorgan Chase & Co | 2024-09-30 | 1.0 |
Avenue Therapeutics Historical Income Statement
Avenue Stock Against Markets
Already Invested in Avenue Therapeutics?
The danger of trading Avenue Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Avenue Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Avenue Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Avenue Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Avenue Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Avenue Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Avenue Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Avenue Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avenue Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. For more detail on how to invest in Avenue Stock please use our How to Invest in Avenue Therapeutics guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avenue Therapeutics. If investors know Avenue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avenue Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share 24.78 | Return On Assets (2.01) | Return On Equity (5.35) |
The market value of Avenue Therapeutics is measured differently than its book value, which is the value of Avenue that is recorded on the company's balance sheet. Investors also form their own opinion of Avenue Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Avenue Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avenue Therapeutics' market value can be influenced by many factors that don't directly affect Avenue Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avenue Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avenue Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avenue Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.